| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2016.71.7397 |
| P698 | PubMed publication ID | 28296582 |
| P50 | author | Stéphane Supiot | Q37839238 |
| Padraig Warde | Q48044256 | ||
| Peter W Chung | Q56979934 | ||
| P2093 | author name string | Jim A Julian | |
| Mark N Levine | |||
| Jean-Paul Bahary | |||
| Himu Lukka | |||
| Charles N Catton | |||
| Matthew B Parliament | |||
| Patrick Cheung | |||
| Colin Tang | |||
| Theodoros Tsakiridis | |||
| Keen Hun Tai | |||
| Shahida Ahmed | |||
| Glenn S Bauman | |||
| Ian S Dayes | |||
| Chu-Shu Gu | |||
| Jarad M Martin | |||
| Jackson S Wu | |||
| Tim K Craig | |||
| Tom B Corbett | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1884-1890 | |
| P577 | publication date | 2017-03-15 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer | |
| P478 | volume | 35 |
| Q90313222 | A Prospective Multi-institutional Phase I/II Trial of Step-wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer |
| Q57480202 | A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526) |
| Q48370850 | Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer |
| Q64287387 | Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet |
| Q99608522 | Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer |
| Q91654934 | Atti Le giornate della ricerca scientificae delle esperienze professionali dei giovani: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) Roma 20-21 dicembre 2019 |
| Q49586879 | Automated prediction of dosimetric eligibility for hypofractionated prostate radiotherapy |
| Q91795852 | COVID-19: Global radiation oncology's targeted response for pandemic preparedness |
| Q92073807 | Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions |
| Q94565363 | Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study |
| Q64950302 | Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. |
| Q90018871 | Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting |
| Q91526499 | Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis |
| Q91845123 | Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts |
| Q64971207 | Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer. |
| Q64287198 | Dramatic polarization in genitourinary expert opinions regarding the clinical utility of positron emission tomography (PET) imaging in prostate cancer |
| Q64228389 | Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer |
| Q58130546 | Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking |
| Q94521775 | Exposure to direct-to-consumer advertising is associated with overestimation of benefits regarding ultrahypofractionated radiation therapy for prostate cancer |
| Q92263631 | Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging |
| Q60920500 | Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives |
| Q64943268 | Futility stopping in non-inferiority trials. |
| Q57280845 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline |
| Q90430172 | Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes |
| Q89639830 | Hypofractionation in prostate cancer radiotherapy: a step forward towards clinical routine |
| Q49618038 | Hypofraktionierte Radiotherapie für die Behandlung des lokal begrenzten Prostatakarzinoms mittleren Risikos |
| Q90195973 | Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial |
| Q89710973 | Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies |
| Q64882929 | Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists. |
| Q55340786 | Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. |
| Q92757983 | Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer |
| Q61806541 | Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study |
| Q92323677 | Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity |
| Q94453486 | Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial |
| Q92487402 | Long term results of the NRG/RTOG 9413: a key study but one of the most confusing study in prostate cancer radiotherapy! |
| Q64235269 | Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer |
| Q64102847 | Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study |
| Q60912877 | Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation |
| Q90636971 | Long-term results of intensity-modulated radiotherapy with three dose-fractionation regimens for localized prostate cancer |
| Q64076380 | Maximizing rectal dose sparing with hydrogel: A retrospective planning study |
| Q64228151 | Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials |
| Q91436232 | Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer |
| Q47155360 | Moderate hypofractionation for prostate cancer |
| Q57112499 | Moderate hypofractionation for prostate cancer |
| Q48238146 | Moderate hypofractionation for prostate cancer: A user's guide. |
| Q89629888 | Moderately HRT vs. CRT for localized prostate cancer using image-guided VMAT with SIB: evaluation of acute and late toxicities |
| Q99712051 | Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial |
| Q89449749 | Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study "GUNMA0702" |
| Q47738916 | Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard. |
| Q55233411 | PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol. |
| Q56519469 | Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer |
| Q58603211 | Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial |
| Q64084857 | Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS) |
| Q90468610 | Phase II Trial of Pure Hypofractionated Radiotherapy in the Treatment of Localized Carcinoma of the Prostate |
| Q92908292 | Physician and facility drivers of spending variation in locoregional prostate cancer |
| Q56528378 | Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? |
| Q92159146 | Prostate cancer - Advantages and disadvantages of MR-guided RT |
| Q90268315 | Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets |
| Q92987333 | Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care |
| Q57475434 | Quality indicators in radiation oncology: proposal of the Spanish Society of Radiation Oncology (SEOR) for a continuous improvement of the quality of care in oncology |
| Q64116246 | Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial |
| Q55038620 | Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't! |
| Q93139677 | Radiation oncology crossword: Genitourinary cancer |
| Q98580682 | Radiation oncology in times of COVID-2019: A review article for those in the eye of the storm - An Indian perspective |
| Q57284584 | Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer |
| Q41276603 | Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives |
| Q89769931 | Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions |
| Q92362703 | Risk-adapted moderate hypofractionation of prostate cancer : A prospective analysis of acute toxicity, QOL and outcome in 221 patients |
| Q98292839 | Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond? |
| Q64324920 | Stereotactic Body Radiotherapy for Primary Prostate Cancer |
| Q57112486 | Stereotactic ablative body radiotherapy in patients with prostate cancer |
| Q90681613 | Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials |
| Q92169143 | Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer |
| Q92756494 | TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol |
| Q96305353 | Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer |
| Q89971939 | Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer |
| Q61807677 | The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States |
| Q92945205 | The evolution of fractionated prostate cancer radiotherapy |
| Q64236901 | The role of radiotherapy in localised and locally advanced prostate cancer |
| Q62746518 | Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415 |
| Q97524797 | Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer |
| Q92945214 | Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial |
| Q47361793 | Updates on the diagnosis and treatment of prostate cancer |
| Q52744328 | Use of hydrogel spacer for improved rectal dose-sparing in patients undergoing radical radiotherapy for localized prostate cancer: First Canadian experience. |
| Q104517654 | [French ccAFU guidelines - update 2020-2022: prostate cancer] |
| Q91896923 | [Toxicity of multimodal regimens in prostate cancer] |
Search more.